تقييم فعالية الواسمات الورمية (CA125,CA19-9) في الكشف عن سرطان المبيض

اَلاء  الفاضل; بسمة الدلال; باولا العبد; عبد الكريم مغمومة

doi:10.5281/zenodo.20252679

Authors

Ala'a Alfade Al Wataniya Private University
Bassma Al-Dallal Al Wataniya Private University
Paula Alabd Al Wataniya Private University
Abd alkareem Maghmomeh Al Wataniya Private University

DOI:

https://doi.org/10.5281/zenodo.20252679

Keywords:

Ovarian Cancer, CA125, CA19-9, Stage, Age

Abstract

Ovarian cancer is a medical condition that is characterized by abnormal growth of cells in one or both ovaries. There are many biomarkers to detect it,monitor its stages, and evaluate the effectiveness of treatment,including tumor markers(CA125,CA19-9).These biomarkers are considered sensitive and specific to evaluate the effectiveness of treatment and the stage of the disease. We collected information on 27 samples of women with ovarian cancer in Hama and Homs governorates on1/2/2024and1/6/2024.The information wasdivided according to age,stage,CA125andCA19-9values.The tumor was placed and the data was analyzed to evaluate these predictive factors during the various stages of the disease using the statistical package for the social science program. It was showed that age is not a predictive factor in determining the stage of the disease but the indicator CA125 was an influential factor in determining the stage while the indicator CA19-9was not significant influential factor. Age was an influential factor at the CA125 and CA19-9 levels

Downloads

Download data is not yet available.

References

[1] U. A. Matulonis, A. K. Sood, L. Fallowfield, B. E. Howitt, J. Sehouli, and B. Y. Karlan, “Ovarian cancer,” Nat. Rev. Dis. Primers, vol. 2, Art. no. 16061, 2016, doi: 10.1038/nrdp.2016.61.

[2] M. Montagnana, M. Benati, and E. Danese, “Circulating biomarkers in epithelial ovarian cancer diagnosis: From present to future perspective,” Ann. Transl. Med., vol. 5, no. 13, Art. no. 276, 2017, doi: 10.21037/atm.2017.05.13.

[3] N. B. Aziz, R. G. Mahmudunnabi, M. Umer, S. Sharma, M. A. Rashid, Y. Alhamhoom, Y. Shim, C. Salomon, and M. J. A. Shiddiky, “MicroRNAs in ovarian cancer and recent advances in the development of microRNA-based biosensors,” Analyst, vol. 145, no. 6, pp. 2038–2057, 2020, doi: 10.1039/C9AN02263E.

[4] W. G. McCluggage, “Morphological subtypes of ovarian carcinoma: A review with emphasis on new developments and pathogenesis,” Pathology, vol. 43, no. 5, pp. 420–432, 2011, doi: 10.1097/PAT.0b013e328348a6e7.

[5] P. Charkhchi, C. Cybulski, J. Gronwald, F. O. Wong, S. A. Narod, and M. R. Akbari, “CA125 and ovarian cancer: A comprehensive review,” Cancers (Basel), vol. 12, no. 12, Art. no. 3730, 2020, doi: 10.3390/cancers12123730.

[6] S. Liu, M. Wu, and F. Wang, “Research progress in prognostic factors and biomarkers of ovarian cancer,” J. Cancer, vol. 12, no. 13, pp. 3976–3996, 2021, doi: 10.7150/jca.47695.

[7] J. Wang, M. Zhu, X. Zhou, T. Wang, and J. Zhang, “Changes in tumor markers, coagulation function and serum VEGF in patients with ovarian cancer and benign ovarian disease,” J. BUON, vol. 25, no. 5, pp. 2287–2292, 2020.

[8] S. Scarà, P. Bottoni, and R. Scatena, “CA 19-9: Biochemical and clinical aspects,” Adv. Exp. Med. Biol., vol. 867, pp. 247–260, 2015, doi: 10.1007/978-94-017-7215-0_15.

[9] N. Yoshikawa, H. Kajiyama, M. Mizuno, K. Shibata, T. Nagasaka, and F. Kikkawa, “Clinicopathologic features of epithelial ovarian carcinoma in younger vs. older patients: Analysis in Japanese women,” J. Gynecol. Oncol., vol. 25, no. 2, pp. 118–123, 2014, doi: 10.3802/jgo.2014.25.2.118.

[10] J. K. Chan, V. Loizzi, Y. G. Lin, K. Osann, W. R. Brewster, and P. J. DiSaia, “Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: What prognostic factors are important?” Obstet. Gynecol., vol. 102, no. 1, pp. 156–161, 2003, doi: 10.1016/S0029-7844(03)00399-5.

[11] F. T. Ali, R. M. Soliman, N. S. Hassan, A. M. Ibrahim, M. M. El-Gizawy, A. A. Y. Mandoh, and E. A. Ibrahim, “Sensitivity and specificity of microRNA-204, CA125, and CA19.9 as biomarkers for diagnosis of ovarian cancer,” PLoS One, vol. 17, no. 8, Art. no. e0272308, 2022, doi: 10.1371/journal.pone.0272308.

[12] N. Sasamoto, A. Babic, B. A. Rosner, R. T. Fortner, A. F. Vitonis, H. Yamamoto, R. N. Fichorova, L. J. Titus, A. Tjønneland, L. Hansen, M. Kvaskoff, A. Fournier, F. R. Mancini, H. Boeing, A. Trichopoulou, E. Peppa, A. Karakatsani, D. Palli, S. Grioni, et al., “Development and validation of circulating CA125 prediction models in postmenopausal women,” J. Ovarian Res., vol. 12, no. 1, Art. no. 116, 2019, doi: 10.1186/s13048-019-0591-4.

[13] P. Gebhart, C. F. Singer, and D. Gschwantler-Kaulich, “CA125 levels in BRCA mutation carriers—a retrospective single center cohort study,” BMC Cancer, vol. 23, no. 1, Art. no. 610, 2023, doi: 10.1186/s12885-023-11116-6.